You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

5 Things You Need to Know About Statin Selection in Patients With HIV Infection

  • Authors: Steven Grinspoon, MD; James A. Underberg, MD
  • CME / ABIM MOC / CE Released: 3/27/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 3/27/2018
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, infectious disease clinicians, endocrinologists, diabetes specialists, PCPs, nurses, pharmacists and all clinicians interested in statin therapy in special populations.

The goal of this activity is to outline the role of statin therapy as a strategy to reduce cardiovascular risk in persons with HIV infection.

Upon completion of this activity, participants will have:

Increased knowledge regarding the:

  • Burden of cardiovascular disease (CVD) in patients with HIV infection
  • The role of statin therapy to prevent CVD in patients with HIV infection

Increased competence related to:

  • The ability to tailor statin therapy in patients with HIV infection


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • James A. Underberg, MD

    Clinical Assistant Professor of Medicine, NYU School of Medicine; Director, Bellevue Hospital Lipid Clinic, NYU Center for Prevention of Cardiovascular Disease, New York, New York

    Disclosures

    Disclosure: James A. Underberg, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amgen Inc.; Lilly; Merck & Co., Inc.; Recombine
    Served as a speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Amgen Inc.; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Received grants for clinical research from: Aegerion Pharmaceuticals; Pfizer Inc.

    Dr Underberg does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Underberg does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Steven Grinspoon, MD

    Professor of Medicine, Harvard Medical School; Director, Program in Nutritional Metabolism and Nutrition Obesity Research Center, Massachusetts General Hospital, Boston, Massachusetts

    Disclosures

    Disclosure: Steven Grinspoon, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Navidea Biopharmaceuticals; Theratechnologies Inc.
    Received grants for clinical research from: Gilead Sciences, Inc.; Kowa Company Ltd.; Navidea Biopharmaceuticals; Theratechnologies Inc.

    Dr Grinspoon does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Grinspoon does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Chair

  • Peter P. Toth, MD, PhD

    Professor of Clinical Family and Community Medicine, University of Illinois; Director of Preventive Cardiology, CGH Medical Center, Sterling, Illinois

    Disclosures

    Disclosure: Peter P. Toth, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amarin Corporation plc; Amgen Inc.; AstraZeneca; Kowa Company Ltd.; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kowa Company Ltd.; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi

Members

  • Judith A. Aberg, MD

    Professor of Medicine; Chief, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York

    Disclosures

    Disclosure: Judith A. Aberg, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Merck & Co., Inc.
    Received grants for clinical research from: Bristol-Myers Squibb Company; GlaxoSmithKline; Gilead Sciences, Inc.

  • Eliot A. Brinton, MD

    Director of Atherometabolic Research, Utah Foundation for Biomedical Research, Salt Lake City, Utah

    Disclosures

    Disclosure: Eliot A. Brinton, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation plc; Amgen Inc.; Aralez Pharmaceuticals; Arisaph Pharmaceuticals; AstraZeneca; Kastle Therapeutics; Kowa Company Ltd.; Merck & Co., Inc.; PTS Diagnostics; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Akcea Therapeutics; Alexion Pharmaceuticals, Inc.; Amarin Corporation plc; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals; Kastle Therapeutics; Kowa Company Ltd.; Lilly; Merck & Co., Inc.; Novo Nordisk; Regeneron Pharmaceuticals, Inc.; Sanofi
    Received grants for clinical research from: Amarin Corporation plc; Kowa Company Ltd.

  • Alan S. Brown, MD

    Advocate Heart Institute, Advocate Lutheran General Hospital, Park Ridge, Illinois

    Disclosures

    Disclosure: Alan S. Brown, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Kastle Therapeutics; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi

  • Sergio Fazio, MD, PhD

    Professor of Medicine; Director of Preventive Cardiology, Oregon Health & Science University, Portland, Oregon

    Disclosures

    Disclosure: Sergio Fazio, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Aegerion Pharmaceuticals, Inc.; Amarin Corporation plc; Amgen Inc.; Invitae Corporation; Kowa Company Ltd.; Merck & Co., Inc.; Sanofi

  • Kevin C. Maki, PhD

    Chief Science Officer, MB Clinical Research, Glen Ellyn, Illinois

    Disclosures

    Disclosure: Kevin C. Maki, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AstraZeneca; DSM; Matinas BioPharma; Sancilio and Company, Inc.

Editor

  • Suzanne Hughes, RN, MSN

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Suzanne Hughes, RN, MSN, has disclosed no relevant financial relationships.

CME Reviewer / Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships: Served as an advisor consultant for: HeartWare; Medtronic; St Jude Medical; Thoratec.


Accreditation Statements


Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.5 contact hour(s) (0.050 CEUs) (Universal Activity Number 0461-0000-17-061-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

5 Things You Need to Know About Statin Selection in Patients With HIV Infection

Authors: Steven Grinspoon, MD; James A. Underberg, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 3/27/2017

Valid for credit through: 3/27/2018

processing....